Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 281
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01381289 | VX-770 Expanded Access Program | ||
| NCT04362761 | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy | ||
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ||
| NCT05455502 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 | ||
| NCT03601637 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del | ||
| NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT05418712 | A Microneurography (MNG) Study of VX-150 in Healthy Participants | ||
| NCT01052194 | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT07538570 | Evaluation of Pain Treatment After Total Knee Arthroplasty | ||
| NCT04977336 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | ||
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | ||
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | ||
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | ||
| NCT05541471 | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin | ||
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ||
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | ||
| NCT07022119 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | ||
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | ||
| NCT01216046 | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects | ||
| NCT07074327 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants | ||
| NCT01830985 | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis | ||
| NCT00973388 | VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers | ||
| NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | ||
| NCT03559062 | A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis | ||
| NCT03525548 | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | ||
| NCT01241760 | VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection | ||
| NCT01863238 | An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis | ||
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT01707290 | Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation | ||
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | ||
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | ||
| NCT03227471 | A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | ||
| NCT06312787 | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT04183790 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older | ||
| NCT05727800 | A Phase 1, First-in-human Study of VX-668 | ||
| NCT01054573 | VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo | ||
| NCT01080222 | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection | ||
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | ||
| NCT02390219 | Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease | ||
| NCT02951195 | A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis | ||
| NCT06794996 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT05653323 | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants | ||
| NCT02508207 | A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT04043806 | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | ||
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | ||
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age |
